ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults

ClinicalTrials.gov ID: NCT00820846

Public ClinicalTrials.gov record NCT00820846. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 3:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants

Study identification

NCT ID
NCT00820846
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Enrollment
299 participants

Conditions and interventions

Conditions

Interventions

  • MVA/HIV62 vaccine Biological
  • Placebo Biological
  • pGA2/JS7 DNA vaccine Biological

Biological

Eligibility (public fields only)

Age range
18 Years to 50 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2008
Primary completion
Jul 31, 2012
Completion
Aug 31, 2014
Last update posted
Aug 8, 2022

2009 – 2014

United States locations

U.S. sites
10
U.S. states
7
U.S. cities
8
Facility City State ZIP Site status
Alabama CRS Birmingham Alabama 35294
Bridge HIV CRS San Francisco California 94143
The Hope Clinic of the Emory Vaccine Center CRS Decatur Georgia 30030
Brigham and Women's Hospital Vaccine CRS (BWH VCRS) Boston Massachusetts 02115-6110
Fenway Health (FH) CRS Boston Massachusetts 02215-4302
Columbia P&S CRS New York New York 10032-3732
New York Blood Center CRS New York New York 10065
University of Rochester Vaccines to Prevent HIV Infection CRS Rochester New York 14642
Vanderbilt Vaccine (VV) CRS Nashville Tennessee 37232-2582
Seattle Vaccine and Prevention CRS Seattle Washington 98109-1024

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00820846, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 8, 2022 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00820846 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →